Faruqi and Faruqui, LLP Logo
Share this page

Bellicum Pharmaceuticals, Inc. (BLCM)

NASDAQ:BLCM

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM).

Aftermarket on January 30, 2018, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States[.]”  Therein, the Company announced that it had “received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.”  BPX-501 is the Company’s lead clinical product candidate designed to improve outcomes for patients undergoing stem cell transplant who lack a matched donor.

On this news, the Company’s share price fell from $8.20 per share on January 30, 2018 to a closing price of $6.08 on January 31, 2018—a $2.12 or a 25.85% drop.

If you invested in Bellicum stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Bellicum Pharmaceuticals, Inc. (BLCM)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 02/06/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.